{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T03:19:09Z","timestamp":1770088749012,"version":"3.49.0"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jill and Kevin Plancher Research Funds"},{"name":"Hasumi International Research Foundation"},{"name":"Jefferson Institute of Molecular Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Uveal melanoma (UM) is the most common intraocular malignancy in adults. Although brachytherapy of the primary tumor provides an approximate 80% five-year survival, with time, nearly half of patients experience predominant liver metastases. It was proposed that malignant cells migrate early and stay dormant as they adapt to the liver microenvironment. We propose that cancer vaccine-mediated activation of UM-targeted immunity in primary UM patients could prevent progression of metastatic disease from dormant cells or malignant seeds. Thus, this study explored DNA vaccination as a measure to educate the immune system to recognize the most common UM-associated Q209L tumor driver mutation in GNAQ and GNA11 G-alpha proteins. Methods: Several DNA constructs encoding mutated GNAQ were developed and tested for activation of UM-reactive T cells in HLA-A2\/Hd transgenic mice and human T cells ex vivo. Results: Constructs containing immune-enhancing PADRE and VP22-derived epitopes boosted T cell responses against mutant GNAQ, which correlated with reduced experimental lung metastases. Ex vivo dendritic cell-mediated T cell activation with vaccine constructs containing optimized structure produced cytolytic T cells that secreted IFN gamma and killed mutated GNAQ-expressing UM cells in vitro. Conclusions: These findings propose the utility of the fusion DNA vaccines in eliciting T cell immunity against UM cells bearing the Q209L mutation in GNAQ\/GNA11 protein to prevent the establishment and progression of metastatic disease.<\/jats:p>","DOI":"10.3390\/cancers18030480","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:12:46Z","timestamp":1770041566000},"page":"480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer Vaccine Targeting Mutated GNAQ-Expressing Uveal Melanoma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1833","authenticated-orcid":false,"given":"Vitali","family":"Alexeev","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2672-9468","authenticated-orcid":false,"given":"Mizue","family":"Terai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-2706","authenticated-orcid":false,"given":"Sergei","family":"Koshkin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9813-7184","authenticated-orcid":false,"given":"Olga","family":"Igoucheva","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, 233 S. 10th Street, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2221-0415","authenticated-orcid":false,"given":"Takami","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: Trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000543151","article-title":"Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1975\u20132020)","volume":"11","author":"Weinberger","year":"2025","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/archopht.119.7.951","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17","volume":"119","author":"Earle","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group (2001). Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch. Ophthalmol., 119, 670\u2013676.","DOI":"10.1001\/archopht.119.5.670"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: A phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study","volume":"39","author":"Pelster","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Bezrookove","year":"2009","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Griewank","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Terai, M., Shimada, A., Chervoneva, I., Hulse, L., Danielson, M., Swensen, J., Orloff, M., Wedegaertner, P.B., Benovic, J.L., and Aplin, A.E. (2021). Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13225749"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shariati, A., Khezrpour, A., Shariati, F., Afkhami, H., Yarahmadi, A., Alavimanesh, S., Kamrani, S., Modarressi, M.H., and Khani, P. (2024). DNA vaccines as promising immuno-therapeutics against cancer: A new insight. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1498431"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ijc.2910390324","article-title":"A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth","volume":"39","author":"Bennett","year":"1987","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/mt.2008.8","article-title":"Mechanisms of immunization against cancer using chimeric antigens","volume":"16","author":"Engelhorn","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/CJI.0b013e3181d75cef","article-title":"CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells","volume":"33","author":"Park","year":"2010","journal-title":"J. Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/gt.2013.17","article-title":"Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine","volume":"20","author":"Igoucheva","year":"2013","journal-title":"Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.170.4.1091","article-title":"Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response","volume":"170","author":"Irwin","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00262-006-0142-x","article-title":"In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line","volume":"55","author":"Santegoets","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2249.1999.00873.x","article-title":"Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein","volume":"116","author":"Escobar","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rivas, A., Samlowski, W., and McCannel, T.A. (2025). Unexpectedly Low Rate of Metastasis and Death Among Patients Treated for Uveal Melanoma with Brachytherapy, Vitrectomy, and Silicone Oil. Cancers, 17.","DOI":"10.3390\/cancers17162683"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","article-title":"Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing","volume":"99","author":"Torsello","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1038\/s41467-024-46906-4","article-title":"Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility","volume":"15","author":"Bhaskarla","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CMR.0000000000000203","article-title":"Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma","volume":"26","author":"Cintolo","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1479-5876-12-55","article-title":"The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors","volume":"12","author":"Rahma","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"kyac001","DOI":"10.1093\/discim\/kyac001","article-title":"Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement","volume":"1","author":"Hopkins","year":"2022","journal-title":"Discov. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Baleeiro, R.B., Dunmall, L.S.C., Liu, P., Lu, S., Lone, Y., Lemoine, N.R., and Wang, Y. (2022). Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.902709"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.4049\/jimmunol.174.8.4812","article-title":"Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide\/MHC complex: Implications for vaccine design","volume":"174","author":"Borbulevych","year":"2005","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.1000629","article-title":"Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition","volume":"185","author":"Cole","year":"2010","journal-title":"J. Immunol."},{"key":"ref_29","first-page":"2536","article-title":"Recombinant virus vaccination against \u201cself\u201d antigens using anchor-fixed immunogens","volume":"59","author":"Irvine","year":"1999","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.vaccine.2008.11.112","article-title":"Development of effective vaccines for old mice in a tumor model","volume":"27","author":"Posnett","year":"2009","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tegeler, C.M., Scheid, J., Rammensee, H.G., Salih, H.R., Walz, J.S., Heitmann, J.S., and Nelde, A. (2022). HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. Cancers, 14.","DOI":"10.3390\/cancers14092260"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:25:48Z","timestamp":1770042348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18030480"],"URL":"https:\/\/doi.org\/10.3390\/cancers18030480","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}